Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.
Nicox remains eligible to receive the same sales milestones of up to US$17.2 million together with tiered royalties of between 5% and 9% of net sales of ZERVIATE by Ocumension. ZERVIATE is currently being evaluated in a confirmatory Phase 3 clinical trial in China by Ocumension, to support a Chinese New Drug Application for the treatment of ocular itching associated with allergic conjunctivitis.
ZERVIATE is the first and only topical ocular formulation of the antihistamine cetirizine and has been commercialized in the United States since March 2020 by Nicox’s exclusive U.S. licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen (Japan). In addition to Ocumension for the Chinese and the majority South East Asian markets, ZERVIATE is also exclusively licensed to Samil Pharmaceutical in South Korea, to ITROM Pharmaceutical Group in certain Gulf and Arab markets and to Laboratorios Grin for Mexico.
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021.
“The Phase 2b Mississippi trial is designed to further explore the NCX 4251 product profile following the encouraging results of the Phase 2 Danube trial,” said Dr. José Boyer, Interim Head of R&D at Nicox, “The Mississippi trial includes a number of clinical endpoints related to signs and symptoms of blepharitis and dry eye disease. We will therefore generate a significant amount of data which will be used to guide the future development of NCX 4251. We will announce the next steps in the development of NCX 4251 following an End-of-Phase 2 meeting with the FDA.”
NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals. The direct administration of NCX 4251 to the eyelids is designed to target the site of the inflammation whilst minimizing the intraocular exposure to the steroid fluticasone, thereby reducing the risk of adverse effects such as increased intraocular pressure and cataract.
Mississippi is a Phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis, and has recruited over 200 patients. The primary outcome measure is the proportion of patients achieving at Day 15 complete cure in eyelid redness, eyelid debris and eyelid discomfort, the hallmark signs and symptoms of blepharitis.
Results Demonstrating Superior Efficacy to Current Standard of Care Presented at World Glaucoma E-Congress 2021
Phase 3 on track with first trial results expected in Q2 2022
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, presented results from the Dolomites Phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater intraocular pressure (IOP) lowering effects in glaucoma patients compared with the current standard of care, latanoprost.
In Dolomites, a dose-response Phase 2 clinical trial evaluating three concentrations of NCX 470 compared to latanoprost ophthalmic solution, 0.005% in 433 patients with open-angle glaucoma or ocular hypertension, NCX 470 0.065% achieved superiority compared to latanoprost 0.005% at all time points on day 28 with up to 1.4 mmHg superior IOP lowering. All tested concentrations of NCX 470 were non-inferior to latanoprost and the dose response of NCX 470 showed improved IOP lowering with each incremental concentration. NCX 470 was safe and well-tolerated with no drug-related serious adverse events and no evidence of treatment-related systemic side effects. The presentation of the results by Dr. David Wirta, one of the clinical investigators in the trial, is available during the World Glaucoma Congress 2021 (June 30 to July 3 2021). The Dolomites trial was completed in late 2019 and the results are detailed here.
“The Phase 2 Dolomites trial demonstrated that NCX 470 has the potential to be a new standard of care for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These impressive data showed superior efficacy against latanoprost, the most prescribed prostaglandin analog for patients with open-angle glaucoma or ocular hypertension, and importantly, also suggested that greater efficacy may be possible at concentrations higher than those used in this dose-ranging trial,” said Dr. Wirta, Medical Director, Eye Research Foundation, Newport Beach, CA, USA and one of the clinical investigators in the Dolomites trial, “NCX 470 was well-tolerated, and the highest dose used in the trial suggests that a higher dose (0.1%) currently being evaluated in Phase 3 has the potential for greater IOP lowering without significant additional risk.”
NCX 470 is currently in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective with these two trials is to demonstrate statistically superior efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% over latanoprost ophthalmic solution 0.005% (first marketed as Xalatan), the most prescribed PGA in the U.S., for the lowering of IOP. Results from the first Phase 3 trial, Mont Blanc, are currently expected in Q2 2022. Results from the second Phase 3 trial, Denali, are now expected in 2023, previously announced as Q4 2022.
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates.
Now approved in 12 countries, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020), Hong Kong (2020) and Taiwan (2021). It is also approved in Brazil, Colombia, Qatar, South Korea, Ukraine and the United Arab Emirates. VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.
Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that results from the Dolomites Phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension will be presented by Dr. David Wirta, Medical Director, Eye Research Foundation (Newport Beach, CA, USA), at the World Glaucoma E-Congress 2021 being held from June 30 – July 3, 2021. Dr. Wirta is one of the clinical investigators in the Dolomites trial.
Dr. Wirta’s presentation will be available from June 30, 2021 on the website of the World Glaucoma E-Congress via a link dedicated to the E-posters.
Nicox’s lead clinical development product candidate, NCX 470 is a novel NO-donating prostaglandin analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.